Skip to main content
If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA?

Despite major advances in RA management, some

Dr. John Cush RheumNow

8 months 3 weeks ago
If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA? Despite major advances in RA management, some patients develop difficult-to-treat RA (D2TRA), characterized by ongoing inflammation and impairment despite multiple therapies. While understanding of the https://t.co/FcF0V82KdT
Giant cell arteritis (GCA) is the most common form of adult vasculitis in the United States and can be subdivided into those with cranial only symptoms, those with large vessel vasculiti/PMR, and those with mixed features. Non-invasive imaging is key in detecting large vessel involvement in GCA, as many of these patients do not experience signs or symptoms specific to this vascular disease (i.e.
Lupus Pregnancy Research: Using AI
The Long View of Diagnostic Delay in Axial Spondyloarthritis

At #ACR25, Abstract #1407 presented a cross-sectional an

Dr. John Cush RheumNow

8 months 3 weeks ago
The Long View of Diagnostic Delay in Axial Spondyloarthritis At #ACR25, Abstract #1407 presented a cross-sectional analysis from the Brazilian Spondyloarthritis Registry (RBE), offering a unique perspective on how diagnostic patterns have evolved over six decades. https://t.co/7ttYXJtfpc
#ACR25 – Day 2 Report
Here are 3 abstracts that caught my eye on Day 2 at #ACR25. Notably these have takeaway message

Dr. John Cush RheumNow

8 months 3 weeks ago
#ACR25 – Day 2 Report Here are 3 abstracts that caught my eye on Day 2 at #ACR25. Notably these have takeaway messages that should support your current practices. https://t.co/xKPAgeWudD https://t.co/Fb16l6A252
PsA: Impact of Sex

Dr. Arthur Kavanaugh highlights the importance of sex on disease characteristics and response to th

Dr. John Cush RheumNow

8 months 4 weeks ago
PsA: Impact of Sex Dr. Arthur Kavanaugh highlights the importance of sex on disease characteristics and response to therapy in psoriatic arthritis, reporting from #ACR25. https://t.co/QtU4iATexR https://t.co/uCJsxYpFTc
Nerandomilast for ILD

Dr. Mike Putman reports on abstract 1662 (Efficacy and Safety of Nerandomilast in Patients with A

Dr. John Cush RheumNow

8 months 4 weeks ago
Nerandomilast for ILD Dr. Mike Putman reports on abstract 1662 (Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial). #ACR25 https://t.co/J0e4SbVgFE https://t.co/dlOM700yVQ
#ACR25 Best Abstracts - Day 2

After a full day at the Chicago Convention center the RheumNow faculty have posted some

Dr. John Cush RheumNow

8 months 4 weeks ago
#ACR25 Best Abstracts - Day 2 After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2. https://t.co/gyIWQXVJ50 https://t.co/vjlK41hzFD
PsA Predictors
ACR 2025 RA Topic Panel
Are we putting the CAR-T before the horse?

CAR T-cells have been a revolutionary development in rheumatology. We have

Dr. John Cush RheumNow

8 months 4 weeks ago
Are we putting the CAR-T before the horse? CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure. https://t.co/niPU5cAojP
The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?
CAR T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area of therapeutic has expanded exponentially. Our growing enthusiasm was slightly dampened though when the FDA required all six approved CAR T-cell therapies in oncology to include a black box warning regarding the risk of second primary malignancies in
×